Holen Sie sich die Stockscreener-App
6.28
2.48%
-0.16
Vorhandelsmarkt:
6.47
0.19
+3.03%
Polaryx Therapeutics Inc Aktie (PLYX) Neueste Nachrichten
Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disea - AD HOC NEWS
Polaryx Therapeutics: Advancing Innovative Therapies for Rare Pediatric Lysosomal Storage Disorders (LSDs) - Minichart
Polaryx Therapeutics (NASDAQ: PLYX) outlines rare pediatric LSD pipeline - Stock Titan
PLYX: Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026 - TradingView
Polaryx Therapeutics, Inc.(NasdaqCM: PLYX) added to S&P TMI Index - marketscreener.com
Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat
PLYX: Polaryx Therapeutics, Inc.Comparative Chart - Zacks Investment Research
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease By Investing.com - Investing.com South Africa
Polaryx Therapeutics (PLYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2 - TipRanks
FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease - Investing.com
Polaryx Therapeutics Says FDA Grants Fast Track Status to PLX-200 - marketscreener.com
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - The Manila Times
FDA Fast Track for PLX‑200 targeting rare pediatric disorder - Stock Titan
Should I buy Polaryx Therapeutics, Inc. (PLYX) - Zacks Investment Research
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Polaryx Therapeutics Stock Rises Amidst Key Clinical Trials Development - timothysykes.com
symbol__ Stock Quote Price and Forecast - CNN
Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat
Polaryx Therapeutics Stock Surges With New Phase Trial Decision - StocksToTrade
PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits
Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Bitget
Biotech backs Krabbe families with research summit and Putt-Putt event - Stock Titan
Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? - Asianet Newsable
Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal
Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat
PLYX Forecast, Price Target & Analyst Ratings | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill
Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com
Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks
Polaryx Therapeutics Inc (PLYX) Stock Price, Quote, News & History - Benzinga
Maxim starts Polaryx at Buy, sees PLX-200 as differentiated - TipRanks
PLYX | Polaryx Therapeutics, Inc. Common Analyst Forecasts - Quiver Quantitative
Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage Disorders - Bitget
PLYX | Polaryx Therapeutics, Inc. Common Insider Trading - Quiver Quantitative
Mstone Partners Healthcare Highlights Polaryx Therapeutics’ Latest Preclinical Data Shared at WORLDSymposium™ - EIN News
Polaryx Therapeutics (PLYX) 10K Form and SEC Filings 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Forecast and Price Target 2026 - MarketBeat
Polaryx Therapeutics (PLYX) Stock Price, News & Analysis - MarketBeat
Polaryx Therapeutics (PLYX) Stock Chart and Price History 2026 - MarketBeat
Insider Buying: G. Landis Acquires Shares of Polaryx Therapeutics Inc (PLYX) - GuruFocus
PLYX Stock Price, News & Analysis - Stock Titan
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
What's Going On With Polaryx Therapeutics Stock Wednesday? - Benzinga
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Polaryx selects CRO for phase 2 trial of rare disease treatment - Investing.com South Africa
What is the current Price Target and Forecast for Polaryx Therapeutics, Inc. (PLYX) - Zacks Investment Research
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans - Bitget
SMJ INTERNATIONAL HOLDINGS INC. (SMJF) Stock, Price, News, Quotes, Forecast and Insights - MSN
Polaryx Therapeutics Surges Amid Strategic Market Moves - StocksToTrade
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):